Results 141 to 150 of about 42,854 (222)

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study

open access: gold, 2022
Shadi Yaghi   +74 more
openalex   +2 more sources

Watching the eye with Mars in sight

open access: yes
Experimental Physiology, EarlyView.
Peter zu Eulenburg   +2 more
wiley   +1 more source

Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients

open access: yesAmerican Journal of Hematology, Volume 100, Issue 11, Page 1972-1982, November 2025.
ABSTRACT Only few data are available regarding the efficacy and safety of thrombopoietin receptor agonists (TPO‐RAs) for treating systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)‐associated immune thrombocytopenia (ITP). We retrospectively assessed the efficacy and safety of TPO‐RAs in 80 adults with ITP in three subgroups: (1)
Cindy Marques   +17 more
wiley   +1 more source

Elevated WBC/HDL Ratio Predicts Poststroke Functional Prognosis

open access: yesBrain and Behavior, Volume 15, Issue 11, November 2025.
Elevated admission white blood cell to high‐density lipoprotein cholesterol ratio (WBC/HDL) independently predicts poor 90‐day functional outcomes in acute ischemic stroke patients, supporting its use as a simple biomarker for early risk stratification.
Haobo Wang   +5 more
wiley   +1 more source

Analysis of Risk Factors for Leukoaraiosis: A Multicenter Retrospective Study

open access: yesBrain and Behavior, Volume 15, Issue 11, November 2025.
This study was to analyze the risk factors clinically associated with the development of leukoaraiosis, and to explore clinical biomarkers that may predict leukoaraiosis. The results demonstrate that age, systolic blood pressure, ischemic stroke, and FT4 level serving as factors affecting the development of leukoaraiosis.
Lingqi Sun   +5 more
wiley   +1 more source

Antiphosphatidylserine antibody as a cause of multiple dural venous sinus thromboses and ST-elevation myocardial infarction [PDF]

open access: yes, 2018
Objective: Rare disease Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by antibodies directed against phos-pholipids on plasma membranes. Through unclear mechanisms, APS confers hypercoagulability.
Marquardt, Caillin W.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy